tbuckley/cabot-search huggingface dataset:
Inhibitor of differentiation-1 (Id1): A novel prognostic and predictive factor in lung adenocarcinoma (AC).
Authors: I. Gil-Bazo, M. Ponz-Sarvisé, M. J. Pajares, M. D. Lozano, J. Agorreta, J. Garcia-Foncillas, C. Behrens, I. I. Wistuba, L. M. Montuenga, A. Calvo
Journal: Journal of Clinical Oncology (2010)

10611 Background: Id1, a basic helix-loop-helix family member is involved in cell differentiation, proliferation, angiogenesis and metastasis in different preclinical models. Although high Id1 levels are found in poor-prognosis breast and prostate cancer human samples, whether Id1 is expressed in non-small cell lung cancer (NSCLC) and whether that potential expression has a predictive/prognostic value has never been investigated. Our objective is to analyze Id1 levels in localized and advanced NSCLC tumors and their impact on progression-free survival (PFS)/time-to- progression (TTP) and overall survival (OS). Methods: 246 NSCLC patients (pts) were studied using formalin-fixed and paraffin-embedded whole section (34) and tissue microarray (212) primary biopsies. Samples were immunohistochemically stained with the anti-Id1 monoclonal antibody 195-14 (1:500) and tumor cell expression was quantified using a validated histoscore system considering intensity and percentage of cells stained. The cut-off value to determine high vs low Id1 levels was the median histoscore. Kaplan-Meier (log rank) was used for statistical comparison. Results: 212 pts with localized NSCLC were treated with surgery (S) (187) or surgery followed by adjuvant chemo-radiotherapy (S-CT-RT) (25). 34 pts with stage IV NSCLC received a median of 4 cycles (1-8) of platinum-based chemotherapy (CT). Among the S group, higher Id1 expression levels were independently associated with a shorter OS among AC pts (p=0.017) but not other histologies. In the S-CT-RT group, the same correlation was found between Id1 and OS among AC (p=0.038). PFS showed no correlation with Id1 in either group. Consistently, in stage IV pts, Id1 maintained its prognostic value (shorter OS in pts with higher levels) only for AC (p=0.003). Moreover, Id1 also correlated with TTP after CT (lower levels, prolonged TTP) in AC pts (p=0.008). Conclusions: In our cohort of NSCLC subjects, Id1 expression was an independent prognostic factor among pts with AC but not other histologies, regardless the stage or treatment received. Moreover, the tumor levels of Id1 in pts with advanced AC may predict clinical benefit from platinum-based CT. Partially funded by Gobierno de Navarra. No significant financial relationships to disclose.
Everolimus with bevacizumab versus interferon alfa-2a plus bevacizumab as first-line therapy in patients with metastatic clear cell renal cell carcinoma.
Authors: A. Ravaud, E. Bajetta, A. C. Kay, D. Pelov, N. Hollaender, N. Rouyrre, J. A. Thompson
Journal: Journal of Clinical Oncology (2010)

TPS238 Background: Bevacizumab + interferon alfa-2a (IFN) has shown clinical benefit as first-line therapy in metastatic RCC (mRCC); however, IFN is associated with toxicities adversely affecting patient quality of life (QoL). Thus, alternative first-line treatment options with improved safety profiles are needed (eg, bevacizumab combined with other targeted drugs). Everolimus is an oral inhibitor of the mammalian target of rapamycin (mTOR), which regulates cell growth and proliferation, metabolism, and angiogenesis and is aberrantly activated in RCC. In the RECORD-1 trial, everolimus demonstrated efficacy in mRCC leading to its approval for treatment of mRCC in patients with disease progression on vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy. Everolimus has a favorable toxicity profile that does not overlap significantly with that of bevacizumab and a complementary mechanism of action that suggests an additive or synergistic clinical benefit. The RECORD-2 (Renal Cell Cancer Treatment with Oral RAD001 Given Daily) trial compares the efficacy and safety of everolimus + bevacizumab compared with IFN + bevacizumab as first-line therapy in patients with mRCC. Methods: RECORD-2 is a randomized, open-label, multicenter phase II trial. Up to 360 patients ≥18 years of age with histologically or cytologically confirmed clear cell mRCC, ≥1 measurable baseline lesion (per RECIST), Karnofsky performance status ≥70%, adequate liver, renal, and bone marrow function, and partial or complete nephrectomy will be enrolled. Patients are randomized 1:1 to receive everolimus 10 mg PO daily + bevacizumab 10 mg/kg IV every 2 wk or IFN (maximum 9 MIU SC 3 doses/wk) + bevacizumab 10 mg/kg IV every 2 wk as first-line therapy until tumor progression, unacceptable toxicity, death, or study discontinuation. The primary endpoint is progression free survival per central review. Overall survival, objective response rate and duration, QoL, exposure to everolimus (in patients randomized to that treatment), and safety will also be assessed. Upon completion, RECORD-2 will be the first randomized trial of combined VEGF and mTOR inhibitors in mRCC. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Bayer, GlaxoSmithKline, Novartis, Pfizer, Roche, Wyeth Novartis Novartis, Pfizer, Roche, Wyeth GlaxoSmithKline, Novartis, Roche
Patients Affected by Changes to Hypertension Guideline—Reply
Authors: Ann Marie Navar-Boggan, Michael J. Pencina, Eric D. Peterson
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Extending primary care hours cuts emergency department visits
Authors: Jacqui Wise
Journal: BMJ (2016)

Providing additional GP appointments outside working hours reduces attendance at hospital emergency departments but may not save the health service money overall, research in PLoS Medicine has shown.1

NHS Greater Manchester provided £3.1m (€3.7m; $4.1m) to enable several groups of primary care practices to provide additional appointments outside regular general practice hours in 2014. The study compared 56 practices (serving 346 024 …
Effect of Drug Interactions and Adherence to Warfarin Therapy on Patients—Reply
Authors: John A. Dodson, J. Michael Gaziano
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Acute Leukaemias with TEL/ABL Fusion: a Subgroup with Poor Prognosis and Prenatal Origin.
Authors: Jan Zuna, Marketa Zaliova, Katerina Muzikova, Claus Meyer, Libuse Lizcova, Zuzana Zemanova, Jana Brezinova, Felix Votava, Rolf Marschalek, Jan Stary, Jan Trka
Journal: Blood (2009)
Geospatial Mapping of Surgical Capacity in Zambia
Authors: Catherine R. deVries, Jenna S. Rosenberg
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study.
Authors: M. Dalla Chiesa, R. Poli, G. Tomasello, S. Lazzarelli, S. Buti, M. Brighenti, F. Negri, A. Curti, A. Auzzani, R. Passalacqua
Journal: Journal of Clinical Oncology (2010)

4142 Background: We previously (ASCO 2007) reported on the high activity of TCF-dd in MGC. This is an update in larger case series. Methods: Patients (pts) with histologically confirmed measurable MGC, ECOG PS 0-1, not previously treated for the advanced disease, received docetaxel 85 mg/m2 (70 mg/m2 after the 19th patient) day 1, cisplatin 75 mg/m2 day 1 (60 mg/m2 after the 19th patient), l-folinic acid 100 mg/m2 day 1 and 2, followed by 5-fluorouracil 400 mg/m2 bolus day 1 and 2, and then 600 mg/m2 as a 22 hour continuous infusion day 1 and 2, every 14 days, plus Pegfilgrastim 6 mg on day 3. Pts aged ≥ 65 years received the same schedule with a dose reduction by 30%. Results: 68 consecutive pts were enrolled (78% male, 22% female; median age: 64, range 38-75; median ECOG PS: 1, range 0-1). Primary end point was overall response rate (ORR). A median of 4 cycles (range 1-6) was administered. 14 pts (21%) required a dose reduction, mostly because of hematologic toxicity and severe asthenia. 34 pts (50%) were treated with full dose without any delay, thus respecting the dose-dense criterion. 61 pts were evaluated for response (4 too early, 1 early suspension because of severe allergic reaction to Docetaxel; 2 early deaths: 1 bowel perforation and 1 sepsis) and all for toxicity. 3 CR, 39 PR, 13 SD and 6 PD were observed, for an ORR (by intention-to- treat) of 62% (95% CI, 48-71). Median TTP was 9,1 months (95% CI, 8-14) and median OS was 13,7 months (95% CI, 10,3- 15,6). Most frequent grade 3-4 toxicities were: neutropenia (32%), thrombocytopenia (16%), anemia (9%) febrile neutropenia (13%), asthenia (26%), diarrhea (10%) and stomatitis (4%). Conclusions: TCF-dd regimen in MGC confirms to be feasible and very active and deserves to be tested in randomized studies. No significant financial relationships to disclose.
56PD Quality of life in TSU-68 study: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline
Authors: B.S. Sohn, S.B. Kim, J.-H. Ahn, K.H. Jung, K.S. Lee, J. Ro, S.-A. Im, Y.-H. Im, H.-S. Song, H.-S. Park, H.C. Chung
Journal: Annals of Oncology (2015)
Predictive factors of ductal spreading in preoperative breast cancer patients.
Authors: K. Hisamatsu, W. Takiyama, T. Mimura, J. Taomoto, Y. Sugiyama, S. Saeki, H. Mukaida, N. Hirabayashi, M. Kaneko, T. Ono
Journal: Journal of Clinical Oncology (2010)

675 Background: To do safety breast conserving surgery, prediction of ductal spreading will be needed. We presented 3D-MRI will be the useful breast imaging tool in diagnosing intraductal spread and tumor size in breast cancer patients by serially step cut section (ASCO 2007-2009). This study was to evaluate factors influencing prediction of ductal spreading by total specimen evaluation, retrospectively. Methods: From April 2005 to November 2009, resected specimens of 165 breast cancer patients were serially step cut and total specimens were microscopically evaluated. Investigated factors influencing prediction of ductal spreading were age (-50, 50-), intrinsic subtype (luminal A+B, HER2-positive, triple negative), patterns of 3D-MRI images (localized pattern and others), presence of preoperative chemotherapy, histological type (ductal, others), histological grade (1, 2+3) and microscopically invasive tumor size (-10 mm, 10 mm-). Results: The rate of histological confirmed ductal spreading with invasive tumor was seen in 56% (92/165 cases) in the total specimens evaluated cases. In these cases, patterns of 3D-MRI was only factor predicting ductal spreading (p < 0.01). Significant correlation of tumor size was detected between 3D-MRI and resected specimen (r > 0.642, p < 0.001), especially in cases with invasive tumor without ductal spreading (r > 0.674, p < 0.001). From July 2000 to November 2009, 543 cases underwent pre-operative 3D-MRI examination. Images were obtained 532 cases (Detection rate 98%). These patients could be divided into two groups according to 3D-MRI images: pattern 1) localized type (292 cases) and 2) others (240 cases). Selection for breast conserving surgery and margin width were based by 3D-MRI images. The proportion of breast-conserved surgery were obtained 90% (487/543 cases) and local failure were seen only 8 cases (local failure rate 1.6%) in 3D-MRI guided surgery. (localized type 3 cases [1%], and others 5 cases [2%] respectively, median follow up 60 months). Conclusions: These results suggest that factor influencing prediction of ductal spreading was pattern of 3D-MRI images. Safety breast conserving surgery will be done especially in cases with localized 3D-MRI pattern of breast cancer. No significant financial relationships to disclose.
Physicians as Citizens
Authors: Michael T Compton, Aneel Advani, Joe McLaughlin, Melissa Tobin-D'Angelo, Elizabeth Tong, Erica Frank
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mutational Profiling Of Myeloid Malignancies For Prediction Of Disease Relapse Following Allogeneic Stem Cell Transplantation
Authors: Alan M Hanash, Sean M. Devlin, Molly Maloy, Kristina M. Knapp, Vincent A. Miller, Doron Lipson, Philip J. Stephens, Geoff A Otto, Roman Yelensky, Michelle K. Nahas, Kai Wang, Ross L. Levine, Marcel R.M. van den Brink, Ann A. Jakubowski
Journal: Blood (2013)
Has the epidemic of allergic contact dermatitis due to methylisothiazolinone reached its peak?
Authors: Z.C. Venables, J.F. Bourke, D.A. Buckley, F. Campbell, M.M.U. Chowdhury, S. Abdul-Ghaffar, C. Green, C.R. Holden, J. McFadden, D. Orton, R.A. Sabroe, J. Sansom, N.M. Stone, S.H. Wakelin, S.M. Wilkinson, G.A. Johnston
Journal: British Journal of Dermatology (2016)

Methylisothiazolinone (MI) is a preservative used in many household and industrial products. There has been an unprecedented global rise in allergic contact dermatitis (ACD) from its presence in personal care products (PCPs).

In 2005 changes to EU legislation allowed MI, used in combination with methylchloroisothiazolinone (MCI), to be used at concentrations of up to 100ppm, 25 times higher than previously permitted. MI was also permitted to be used alone, whereas previously it was only used in combination with MCI in a 3:1 mix.1This resulted in the chain of events that led to the current MI allergy epidemic.By 2010, the first case series of ACD to MI as a cosmetic allergen was published.

This article is protected by copyright. All rights reserved.
The Effects of Population Size Histories on Estimates of Selection Coefficients from Time-Series Genetic Data
Authors: Ethan M. Jewett, Matthias Steinrücken, Yun S. Song
Journal: Molecular Biology and Evolution (2016)

Many approaches have been developed for inferring selection coefficients from time series data while accounting for genetic drift. These approaches have been motivated by the intuition that properly accounting for the population size history can significantly improve estimates of selective strengths. However, the improvement in inference accuracy that can be attained by modeling drift has not been characterized. Here, by comparing maximum likelihood estimates of selection coefficients that account for the true population size history with estimates that ignore drift by assuming allele frequencies evolve deterministically in a population of infinite size, we address the following questions: how much can modeling the population size history improve estimates of selection coefficients? How much can mis-inferred population sizes hurt inferences of selection coefficients? We conduct our analysis under the discrete Wright-Fisher model by deriving the exact probability of an allele frequency trajectory in a population of time-varying size and we replicate our results under the diffusion model. For both models, we find that ignoring drift leads to estimates of selection coefficients that are nearly as accurate as estimates that account for the true population history, even when population sizes are small and drift is high. This result is of interest because inference methods that ignore drift are widely used in evolutionary studies and can be many orders of magnitude faster than methods that account for population sizes.
Мультипотентный гепатопротектор Ларнамин в клинической практике
Authors: N.B. Huberhrits, O.Ye. Klochkov, P.H. Fomenko, N.V. Bieliaieva
Journal: GASTROENTEROLOGY (2016)

В статье проанализирована литература о физиологических механизмах действия и доказательной базе L-орнитин-L-аспартата — действующего вещества препарата Ларнамин. Продемонстрированы многогранные свойства препарата: дезинтоксикационное, анаболическое, гепатопротекторное, вазодилатирующее, способность стимулировать продукцию соматотропного гормона и инсулина. Описаны результаты клинических исследований, подтверждающие эффективность L-орнитин-L-аспартата при печеночной энцефалопатии, хронических диффузных заболеваниях печени, в т.ч. при алкогольной и неалкогольной жировой болезни печени. Препарат эффективен также при остром панкреатите, алкогольной интоксикации. Переносимость препарата удовлетворительная, вероятность и выраженность побочных эффектов минимальны.
Balancing the Evidence Base on Coronary Stents
Authors: Eric R. Bates
Journal: New England Journal of Medicine (2016)

The development of percutaneous coronary intervention (PCI) transformed the treatment of obstructive coronary artery disease by creating a less invasive revascularization option to coronary-artery bypass grafting.1 In the first decade of PCI, clinical outcomes associated with the use of balloon catheters were limited by operator learning curves, early interventional equipment, inadequate antithrombotic therapy, acute vessel closure requiring emergency bypass surgery in 6% of patients, and target-lesion restenosis within 6 months in half the patients. In the second decade, bare-metal stents mostly solved the problem of acute closure by scaffolding the arterial wall and reduced restenosis rates to approximately 20% but . . .
Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN
Authors: Elena Tenedini, Isabella Bernardis, Valentina Artusi, Lucia Artuso, Enrica Roncaglia, Paola Guglielmelli, Lisa Pieri, Costanza Bogani, Flavia Biamonte, Elisa Bianchi, Alessandro Pancrazzi, Carmela Mannarelli, Tiziana Fanelli, Giada Rotunno, Guidantonio Malagoli Tagliazucchi, Sergio Ferrari, Rossella Manfredini, Alessandro M Vannucchi, Enrico Tagliafico
Journal: Blood (2013)
MB-14MOLECULAR AND PROGNOSTIC HETEROGENEITY WITHIN<i>MYC</i>AND<i>MYCN</i>AMPLIFIED MEDULLOBLASTOMAS
Authors: Janet Lindsey, Rebecca Hill, Ed Schwalbe, Emily Shrimpton, Christopher Howell, Gholamreza Rafiee, Stephen Crosier, Amanda Smith, Sarra Ryan, Daniel Williamson, Simon Bailey, Steven Clifford
Journal: Neuro-Oncology (2016)

MYC and MYCN are the most commonly amplified oncogenes in medulloblastoma; their association with poor prognosis in disease-wide studies has supported their adoption as high-risk disease biomarkers in current clinical trials. However, recent observations suggest some patients with MYC/MYCN amplified tumours achieve long term survival and may suffer unnecessary side effects associated with intensified therapies. To further understand this heterogeneity, we characterised the molecular, clinical and pathological features of focussed cohorts of MYC (n = 37) and MYCN (n = 57) amplified tumours (identified by FISH and/or copy number profiling), and assessed their associations with disease outcome. Within the MYCN cohort (24 MYCNSHH; 24 MYCNGroup4; 3 MYCNGroup3; 6 NA), patient survival was subgroup-dependent; patients with MYCNGroup4 and no other clinico-pathological risk factors (subtotal resection, metastatic disease or LCA pathology) had a favourable event free survival (EFS). In contrast, MYCNSHH was associated with LCA (MYCNSHH vs MYCNGroup4, p< 0.0001) and a dismal EFS regardless of additional risk factors. TP53 mutation was a frequent feature of MYCNSHH (12/23), usually in conjunction with Chromosome 17p loss and GLI2 amplification, and conferred a quicker time to progression within MYCNSHH (p = 0.05). LCA pathology was the poorest prognostic factor in MYC-amplified tumours. The majority (20/30) of sub-grouped MYC-amplified tumours were MYCGroup3. Rare MYCGroup4 tumours (5/30), had fewer (<50%) amplified tumour cells and a better EFS than MYCGroup3 (p = 0.04). These data highlight the importance of subgroup identification as a basis for refined stratification of medulloblastoma risk using MYC/MYCN amplification, and suggest that MYC/MYCNGroup4 as isolated risk-factors do not confer high-risk disease.